This is a controlled, open study designed to compare the effects of dual-release hydrocortisone preparations versus conventional glucocorticoid therapy on clinical, anthropometric parameters, metabolic syndrome, hormonal profile, bone status, quality of life, reproductive, sexual and psychological functions and treatment compliance in patients affected by congenital adrenal hyperplasia due to 21 OH deficiency.

Start Date11 Aug 2016

Sponsor / Collaborator

Università degli Studi di Napoli Federico II

IRCT2016053028173N2 / CompletedPhase 3IIT

The Effect of local Injection of Cortone on Pain preception after Root Canal treatment of teeth with Irreversible Pulpits

Start Date05 Aug 2016

Sponsor / Collaborator

Tabriz University of Medical Sciences

NCT03580148 / CompletedPhase 2/3IIT

A Randomized Trial of Cortisone Injection Versus Bone Marrow Aspirate Injection Therapy for Glenohumeral Osteoarthritis

This randomized trial seeks to investigate the difference if any between cortisone injection versus bone marrow aspirate injection in the glenohumeral joint of patients with confirmed osteoarthritis. The investigators hope that results from a prospective randomized controlled pilot study on bone marrow aspirate (BMA) glenohumeral joint (GHJ) injections will provide valuable early information on an alternative treatment for GHJ osteoarthritis (OA). This novel study will also contribute clinical data to the growing pool of research around BMA in the treatment of osteoarthritis. This study has the potential to uncover a new and more effective therapy to add to the arsenal of an orthopaedic surgeon in the management of GHJ OA. This would provide improved care and treatment for those disabled by GHJ OA. Additionally, this knowledge would be applicable to a variety of medical practitioners who treat GHJ OA from the general orthopaedic surgeon to pain subspecialists.

Start Date08 Oct 2015

Sponsor / Collaborator

Women's College Hospital

[+1]

100 Clinical Results associated with Cortisone acetate

100 Translational Medicine associated with Cortisone acetate

100 Patents (Medical) associated with Cortisone acetate

17,604

Literatures (Medical) associated with Cortisone acetate

02 Dec 2024·Journal of biomolecular structure & dynamics

Computational prediction of 11β-hydroxysteroid dehydrogenase inhibitors from n-butanol fraction of Blighia welwetschii (Hiern) leaf for the management of type-2 diabetes

Article

Author: Bodun, Damilola S. ; Aribigbola, Temitope C. ; Omoboyowa, Damilola A.

Human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) is an enzyme that catalyzes the generation of active cortisol from cortisone, thus regulating the availability of glucocorticoids for the steroid receptor. The involvement of this process in insulin insensitivity has established the catalyst as therapeutic target in type-2 diabetes management. Herein, potent antagonists of 11β-HSD-1 were predicted from bioactive compounds identified from n-butanol fraction of B. welwitschi leaf using chromatography method (HPLC). Molecular docking, MM/GBSA evaluation, autoQSAR modeling, e-pharmacophore modeling, and molecular dynamics simulation of the bioactive compounds were carried out against 11β-HSD-1 employing Schrodinger suite (2017-1). Seven out of the ten bioactive compounds from the fraction showed a higher degree of binding affinity against 11β-HSD-1 compared with the co-crystalized ligand. The post-docking analysis revealed strong interaction due to the hydrogen bond formation between the molecules and amino acid present at the catalytic site of 11β-HSD-1. Rutin showed the highest binding affinity (-13.980 kcal/mol) among the hits comparable to the co-crystalized ligand (-7.576 kcal/mol). The binding free energy (ΔG^bind) evaluation validates the inhibitory potential of the docked complexes, which exclusively confirmed cyaniding-3-o-glucoside (-62.022 kcal/mol) with the highest binding energy followed by rutin (-59.629 kcal/mol). The molecular dynamics simulations predicted the stability of rutin and quercetin-3-o-glycoside complex with 11β-HSD-1 through 100 ns with minimum fluctuation and more H-bond observed between the two top scored 11β-HSD-1-compound complexes compared to the 11β-HSD-1-co-crystalized ligand complex. The pharmacokinetic profile revealed that the hit compounds are promising drug candidates except for rutin which violated more than one Lipinski's rule of five. This study revealed that bioactive compounds identified from B. welwitschi leaves demonstrated good inhibitory potential against 11β-HSD-1. Therefore, these bioactive molecules require experimental validation as 11β-HSD-1 antagonists for type 2 diabetes management.Communicated by Ramaswamy H. Sarma.

01 Dec 2024·REPRODUCTIVE BIOMEDICINE ONLINE

Corticosteroids, androgens, progestogens and oestrogens in the endometrial microenvironment, and their association with endometrial progression and function

Article

Author: Lopez-Nogueroles, Marina ; Meseguer, Marcos ; Diaz-Gimeno, Patricia ; Pellicer, Nuria ; Devesa-Peiro, Almudena ; Labarta, Elena ; Marti-Garcia, Diana ; Sebastian-Leon, Patricia

RESEARCH QUESTION:

How does the intracrine action of progestagens, oestrogens, androgens and corticosteroids affect endometrial tissue progression and function?

DESIGN:

In this prospective observational study, 76 patients (<50 years old, no uterine pathologies and at least one failed IVF cycle) undergoing endometrial biopsy collection for endometrial evaluation between 2018 and 2021 were included. The concentrations of 11 steroid metabolites (cortisone, cortisol, progesterone, oestrone, 2-methoxyestrone, oestradiol, oestriol, testosterone, androstenedione, 17α-hydroxyprogesterone and 17-hydroxypregnenolone) were measured by ultra-performance liquid chromatography-tandem mass spectrometry in the endometrial tissue samples collected during the mid-secretory phase. Endometrial dating and reproductive outcomes (relative to the next good-quality fresh or frozen embryo transfer after the biopsy) were analysed in relation to endometrial steroid concentrations using Barnard's test; correlations between metabolite concentrations were measured by Pearson's correlation co-efficient.

RESULTS:

Endometrial cortisol concentrations increased with age, whereas oestrone and 17α-hydroxyprogesterone concentrations had inverse relationships with body mass index (all P < 0.05). No statistically significant differences were found in age or body mass index related to endometrial progression and reproductive outcomes. Low endometrial progesterone (<40.07 μg/g), along with high endometrial cortisol (>2.18 ng/g) and testosterone concentrations (≥0.52 ng/g), were mainly associated with out-of-phase endometria. Although low oestrone (<21.27 ng/g) and high androstenedione endometrial concentrations (≥1.35 ng/g) impaired reproductive success, low oestradiol (<1.15 ng/g) endometrial concentrations favoured conception (all P < 0.05).

CONCLUSIONS:

In addition to progesterone and oestrogens, other steroid hormones are involved in intracrine signalling, and are probably necessary for acquiring adequate endometrial competence and supporting conception.

26 Nov 2024·CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Stability of steroid hormones in dried blood spots (DBS)

Article

Author: Olthof, Anouk ; Heijboer, Annemieke C. ; Boelen, Anita ; Hillebrand, Jacquelien J. ; Wickenhagen, Wjera V.

Abstract:

Objectives:

Steroid hormone levels of patients may be monitored via dried blood spot (DBS) sampling at home. Stability of steroid hormones in DBS samples, however, needs to be established.

Methods:

DBS samples from healthy volunteers were collected and stored at various temperatures. Steroid hormone concentrations in DBS were measured directly, at day 2, day 7 and day 14 following storage at 37 °C and after 7 days, 14 days, 3 months and 6 months following storage at −20 °C, 4 °C and room temperature (RT). Cortisol, cortisone, corticosterone, testosterone, androstenedione, and 17-hydroxyprogesterone (17-OHP) were assessed using LC-MS/MS.

Results:

All steroids were stable (±15 %) up to 14 days when stored at 37 °C, except for cortisone (only stable until 2 days). All steroids were stable up to 6 months when stored at −20 °C, 4 °C and RT. However, there were some exceptions, for androstenedione at RT (only stable until 7 days), for 17-OHP when stored at −20 °C (only stable until 3 months), for cortisone at RT and 4 °C (only stable until 14 days), and cortisol at RT (only stable until 3 months).

Conclusions:

Overall, we demonstrated stability of steroid hormone concentrations in DBS under various conditions which may be encountered during shipping to the diagnostic laboratory and during long-term storage before analysis.

News (Medical) associated with Cortisone acetate

25 Jul 2023

·www.sciencedaily.com

How the brain detects and regulates inflammation

How does the brain adapt our behavior in response to an infection or injury? Scientists have revealed the existence of a circuit involved in sensing and also in the regulation of the anti-inflammatory response orchestrated by different brain regions. This circuit detects inflammation in the blood and organizes and regulates the immune response. It embodies a two-way connection between the brain and immune system. How does the brain adapt our behavior in response to an infection or injury? A multidisciplinary team of scientists from the Institut Pasteur, CNRS and Inserm have revealed the existence of a circuit involved in sensing and also in the regulation of the anti-inflammatory response orchestrated by different brain regions. This circuit detects inflammation in the blood and organizes and regulates the immune response. It embodies a two-way connection between the brain and immune system. The results were published on June 5, 2023 in the journal Neuron. Whenever infections or injuries occur, the immune system is triggered to control the infection and repair damaged tissue. This process involves the release of pro-inflammatory mediators that inform the brain of the body's immune status and coordinate the immune response. In response to this signal, the brain triggers a complex reaction known as "sickness behavior" whose purpose is to reassign energy to the body's different systems. This state is associated with behavioral changes including social avoidance and lethargy, metabolic adjustments such as fever and loss of appetite, and the release of hormones such as cortisone, to increase resistance to infection while also regulating immune responses. In this study, a multidisciplinary group consisting of neurobiologists and immunologists from the Institut Pasteur, Inserm and the CNRS discovered a novel circuit used by the brain to measure inflammation levels in the blood and, in response to this, regulate inflammation. A region of the brainstem known as the vagal complex directly detects levels and types of inflammatory hormones in the bloodstream. This information is then relayed to neurons in another region of the brainstem called the parabrachial nucleus, which also receives information related to pain and certain aversive or traumatic memories. In turn, these neurons activate neurons in the hypothalamus leading to a rapid increase in cortisone, a hormone with anti-inflammatory properties, in the blood. The scientists used state-of-the-art neuroscience approaches to identify this circuit, which enabled them to individually observe the neurons involved during inflammation. The experts observed how the activity of specific neurons in the parabrachial nucleus could regulate the production of white blood cells involved in the immune response. "This research demonstrates that neural activity in the brain alone can have a powerful effect on the development of immune responses during infection or injury. It therefore provides a clear example of the powerful two-way connection between the body and brain. It also fuels our ambition to discover the impact of our brain on the way we interact with microbes, fight off pathogens and heal wounds," explains Gérard Eberl, Head of the Institut Pasteur's Microenvironment and Immunity Unit. The discovery of this circuit opens up new opportunities for research that will jointly contribute to the fields of neurobiology and immunology: "This study gives us additional tools to better understand the impact of systemic inflammation on our brain, mood and on certain neurodegenerative processes," adds Gabriel Lepousez, a neurobiologist in the Perception and Memory Unit (Institut Pasteur/CNRS). Given the established role of the parabrachial nucleus in aversive memory processes, potential infectious threats could be averted if this circuit is reactivated by the memory of past inflammatory or aversive experiences. Drawing on this neuro-immune communication, the immune system could therefore benefit from the brain's ability to predict and anticipate threats in our environment. This research was funded by the organizations cited above and also by AG2R-LA MONDIALE and MTRL.

09 Jun 2023

·www.globenewswire.com

Crinetics to Highlight Broad Pipeline at ENDO 2023

Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for EntrepreneurshipSAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the Endocrine Society’s annual meeting, which is being held June 15-18, 2023 in Chicago, Illinois. Two presentations will provide additional clinical evidence and patient-reported data for paltusotine, an experimental, once-daily, oral, small molecule somatostatin receptor type 2 (SST2) agonist in Phase 3 clinical development for the treatment of acromegaly. An upcoming oral presentation will review previously reported two-year data from the company’s ACROBAT Advance open-label extension study of paltusotine in acromegaly. The presentation will be delivered by Monica R. Gadelha, M.D., Ph.D., professor of endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro and a principal investigator in the Phase 2 ACROBAT program. In addition to the maintenance of IGF-1 levels in Advance study participants, Dr. Gahelha will present an analysis of symptom control and other patient-reported outcomes as assessed using the Acromegaly Symptom Diary. In addition, Crinetics will highlight the results of in vivo studies from preclinical programs developing: (1) a parathyroid hormone receptor type 1 (PTH1R) antagonist for the treatment of primary hyperparathyroidism; and (2) a thyroid-stimulating hormone receptor (TSHR) antagonist for the treatment of Graves’ disease, an autoimmune disorder that can cause hyperthyroidism and the associated thyroid eye disease (orbitopathy). Additional details on the presentations are shown below: Title:Oral, Once-Daily, Paltusotine (Non-Peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy in Patients with Acromegaly is Associated with Long-Term Biochemical and Symptom Control and is Preferred Over Injectable Somatostatin-Receptor LigandsDate/Time:June 15th from 10:00 AM - 11:30 AM CTLocation:Oral Session OR01 - Neuroendocrinology: Molecular and Physiological Aspects Title:Discovery and Characterization of Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonists for the Treatment of Graves’ DiseaseDate/Time:June 16th from 12:00pm - 1:00pm CTLocation:Poster FRI-546 in Session P54 - Thyroid Biology & Cancer: Thyroid Autoimmunity Title:Effects of an Orally Bioavailable Nonpeptide Parathyroid Hormone Receptor Type 1 (PTH1R) Antagonist in Rodent Models of Primary Hyperparathyroidism (PHPT)Date/Time:June 17th from 1:00pm - 2:00pm CTLocation:Poster SAT-182 in Session P66 - Bone and Mineral Metabolism: Hyperparathyroidism Title:Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oral Paltusotine, a Non-Peptide, Selective Somatostatin Receptor Subtype 2 AgonistDate/Time: June 17th from 1:00pm - 2:00pm CTLocation:Poster SAT-628 in Session P87 - Late Breaking Poster Abstracts Title:Waking Salivary 11-Hydroxyandrostenedione and Cortisone as a Novel Non-invasive Test for Adrenal InsufficiencyDate/Time:June 18th from 8:00am - 9:30am CTLocation:Oral Session OR30 - Adrenal Insufficiency and Congenital Adrenal Hyperplasia In addition, on June 15, 2023, the Endocrine Society’s president, Ursula B. Kaiser, M.D. will present R. Scott Struthers, Ph.D., founder and CEO of Crinetics, with the Society’s John D. Baxter Prize for Entrepreneurship for Dr. Struthers’ contributions to drug discovery and development in endocrine diseases. During the award session, Dr. Struthers will present a lecture titled, “Adventures Discovering Nonpeptide Oral Drugs Acting at Peptide Hormone Receptors.” The Baxter Prize was established in memory of Endocrine Society Past President John D. Baxter, M.D., a world-renowned scientist best known for being the first to clone the human growth hormone gene. Commenting on the award, Dr. Struthers explained, “John Baxter, with one foot in his academic role and another in founding multiple companies, was an icon for the key role that entrepreneurship can play in advancing the field of endocrinology. At Crinetics, we share Dr. Baxter’s vision of harnessing the entrepreneurial spirit of world-class scientists and physicians to repeatedly discover, develop and deliver novel therapies for endocrine disorders with high unmet medical need. I would like to thank the Endocrine Society for awarding this prize, which is a testament to all of the groundbreaking work being done by the Crinetics team.” The posters and oral presentations will be made available on the Crinetics website in accordance with the ENDO embargo policy. For attendees of ENDO 2023, Crinetics staff will be available to address questions and discuss pipeline programs at the company booth (#1623). About Crinetics Pharmaceuticals   Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in Phase 1 clinical studies for CRN04894, an investigational, oral ACTH antagonist in development for the treatment of Cushing’s disease and congenital adrenal hyperplasia and for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist in development for congenital hyperinsulinism. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts.   Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the plans for the clinical development of paltusotine, CRN04777 and CRN04894, including the therapeutic potential and clinical benefits thereof. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, topline data that we report may change following a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, and the FDA and other regulatory authorities may not agree with our interpretation of such results; we may not be able to obtain, maintain and enforce our patents and other intellectual property rights, and it may be prohibitively difficult or costly to protect such rights; the COVID-19 pandemic and other geopolitical events may disrupt Crinetics’ business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; unexpected adverse side effects or inadequate efficacy of the company’s product candidates that may limit their development, regulatory approval and/or commercialization; the company’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of Crinetics’ clinical studies and nonclinical studies; regulatory developments in the United States and foreign countries; clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics’ drug candidates may not advance in development or be approved for marketing; Crinetics may use its capital resources sooner than expected; any future impacts to our business resulting from geopolitical developments outside our control; and the other risks and uncertainties described in the company’s periodic filings with the SEC. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading “Risk Factors” in Crinetics’ periodic reports, including its annual report on Form 10-K for the year ended December 31, 2022. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contacts: Chas Schultz VP, IR & Corporate Communications cschultz@crinetics.com (858) 450-6464 Investors / Media: Corey Davis LifeSci Advisors, LLC cdavis@lifesciadvisors.com (212) 915-2577 Aline Sherwood Scienta Communications asherwood@scientapr.com(312) 238-8957

Phase 2Phase 1Phase 3

12 May 2023

·www.prnewswire.com

The Health and Wellness Brand Channeling Slow Simmering, Ancestral Wisdom into a Fast-Paced, Modern Environment

Gelpro Australia Is Creating Accessible Supplements That Sustainably Utilize Mother Nature's Best Healing Ingredients FORT LAUDERDALE, Fla., May 12, 2023 /PRNewswire/ -- The modern, science-driven world has countless answers to many of humanity's biggest problems. From healthcare to technology, scientists are discovering new ways to improve life every day. However, a genuine and effective application of modern science shouldn't be used in a vacuum. It should be combined with the well-established wisdom of the past — especially when it comes to something as ancient as health and wellness. This is the philosophy that the creators of Gelpro Australia have had in mind from the very beginning of their brand. "Gelpro Australia is a family-run health brand based on ancestral wisdom," explains company CEO Nagib Kassis. Kassis himself stepped back from a high-flying life as a corporate executive over a decade ago when he was diagnosed with rheumatoid arthritis. The young professional was informed that he would remain on NSAIDs indefinitely and could be facing joint replacements by his 30s. Nagib's brother-in-law, Anthony, was facing his own personal health struggles. The kickboxer and muscle-training fanatic had hurt his shoulder and was facing a lengthy recovery timeline laced with cortisone injections and surgeries. The siblings turned to the ancient wisdom of the past in search of a solution. "We knew we had nothing to lose," explains Nagib, "so we started drinking homemade bone broth and massively increasing our collagen uptake. Our health began to improve, not just in the obvious areas, but all around." The discovery led the two brothers to develop their own line of elite collagen and whole food supplement products. From day one, the goal with each product formula was simple: to channel the slow-simmering ancestral wisdom of their forefathers into accessible products that fit into a busy modern lifestyle. "Our products have been created to remind the world that our ancestors had most of the answers," says Nagib, "In most cases, you can utilize the wonders of nature for your wellness journey. Nagib clarifies that this doesn't mean science is left out of the Gelpro approach. All of the brand's formulations are backed by research and science. They use this as a way to reinforce the efficacy of their ingredients, all of which are sourced based on the wisdom of their ancestral heritage. "We believe that natural ingredients have a strong place in the market," Nagib emphatically declares, "None of our formulations use synthetic ingredients, fillers, or flowing agents, because we focus on ingredient quality. With Gelpro, we're channeling the simple, effective, and natural health and wellness of past generations into a modern format that can improve any lifestyle." About Gelpro Australia Gelpro Australia™ Pty Ltd is a family-run Australian health and wellness company that operates with a holistic approach to health and sustainability at the forefront of its brand philosophy. The company was founded by two brothers-in-law in 2014 after they individually went through their own health challenges and discovered the healing capabilities of natural, high-quality health solutions rooted in ancestral wisdom. Since its inception, Gelpro has become known for its robust line of top-shelf collagens and whole food supplements. The brand is recognized as a health and wellness market leader and educator in the Land Down Under. Learn more at gelatinaustralia.com.au. Media Contact: Nagib Kassis T: 0452 334 489 [email protected] SOURCE Gelpro

100 Deals associated with Cortisone acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D00973	Cortisone acetate	S01BA03 H02AB10	DB01380

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Inflammation	US	Merck & Co., Inc.	13 Jun 1950
Pruritus	US	Merck & Co., Inc.	13 Jun 1950

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis